TFG Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

TFG Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-750,000	Closed	-$2.04M	–	43
2020 Q1	$2.04M	Sell	750,000 -107,311	-13%	-$356K	0.35%	29
2019 Q4	$1.03M	Buy	857,311 +357,311	+71%	+$381K	0.15%	35
2019 Q3	$755K	Hold	500,000	–	–	0.13%	40
2019 Q2	$2.01M	Hold	500,000	–	–	0.29%	40
2019 Q1	$2.15M	Hold	500,000	–	–	0.27%	39
2018 Q4	$2.88M	Buy	500,000 +200,000	+67%	+$1.48M	0.45%	35
2018 Q3	$4.07M	Buy	+300,000	New	+$3.14M	0.49%	34

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TFG Asset Management's ADAP Position: Q2 2020 in Review

TFG Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2020, closing a stake of 750,000 shares — an estimated $2.04M sold.

TFG Asset Management first reported a position in ADAP in Q3 2018 and held it in 7 quarters. The position peaked at $4.07M in Q3 2018. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2020.

TFG Asset Management reported no remaining Adaptimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
TFG Asset Management sold 750,000 Adaptimmune Therapeutics shares in Q2 2020, an estimated $2.04M.
TFG Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 7 quarters.
TFG Asset Management's Adaptimmune Therapeutics position peaked at $4.07M in Q3 2018.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2020.

Based on TFG Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.